Xilio Therapeutics (XLO) Accounts Payables (2020 - 2026)
Xilio Therapeutics (XLO) posted Accounts Payables of $1.1 million for Q1 2026, down 66.41% sequentially from $3.2 million in Q4 2025, and down 53.23% YoY from $2.3 million in Q1 2025.
Xilio Therapeutics (XLO) Accounts Payables (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Accounts Payables for 7 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Accounts Payables fell 53.23% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 53.23% YoY) and the FY2025 annual result came in at $3.2 million, up 23.08% from the prior year.
- Accounts Payables declined to $1.1 million in Q1 2026 per XLO's latest filing, from $3.2 million in the prior quarter.
- Over five years, Accounts Payables peaked at $4.1 million in Q2 2025 and troughed at $746000.0 in Q1 2024.
- A 5-year average of $1.9 million and a median of $1.8 million in 2022 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2025: Accounts Payables sank 66.4% in 2023, then soared 224.13% in 2025.
- Over 5 years, Accounts Payables stood at $3.1 million in 2022, then sank by 66.4% to $1.0 million in 2023, then surged by 145.14% to $2.6 million in 2024, then advanced by 23.08% to $3.2 million in 2025, then plunged by 66.41% to $1.1 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.1 million, $3.2 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | 2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.32 Mn |
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 3.17 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 4.10 Mn |
| Mar 31, 2025 | 2.28 Mn |
| Dec 31, 2024 | 2.57 Mn |
| Sep 30, 2024 | 972,000.00 |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | 746,000.00 |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | 1.49 Mn |
| Jun 30, 2023 | 945,000.00 |
| Mar 31, 2023 | 2.01 Mn |
| Dec 31, 2022 | 3.13 Mn |
| Sep 30, 2022 | 1.81 Mn |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 2.32 Mn |
| Dec 31, 2021 | 3.14 Mn |
| Sep 30, 2021 | 3.82 Mn |